At Travere Therapeutics, our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.
Volume:52 Week High:52 Week Low:
Data Provided by Refinitiv. Minimum 15 minutes delayed.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), EveryLife Foundation for Rare Diseases, Global Genes, and rare disease advocates and
SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in February and March: SVB Leerink 10th Annual Global Healthcare Conference Date: Wednesday, February
SAN DIEGO , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease